Payment overview · 2025
General Payments
$427.86
13 reported records · 7 companies
Healthcare provider profile · identity verified
Mayra M. Casta, M.D.
Allopathic & Osteopathic Physicians|General Practice · TAMPA, FL · NPI 1821046285
Verified facts
What the public records show
CMS Open Payments records show Mayra M. Casta, M.D. received $427.86 in general payments during 2025 across 13 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $151.69 | 35.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $146.37 | 34.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.53 | 15.6% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.06 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.58 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.88 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.75 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $427.86 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $151.69 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $146.37 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.53 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 546 | 191 |
| Losartan Potassium | Losartan Potassium | 490 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 111 |
| Gabapentin | Gabapentin | 342 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 100 |
| Metformin Hcl | Metformin Hcl | 288 | 101 |
| Omeprazole | Omeprazole | 270 | 84 |
| Famotidine | Famotidine | 267 | 96 |
| Hydrochlorothiazide | Hydrochlorothiazide | 253 | 86 |
| Lisinopril | Lisinopril | 252 | 90 |
| Diclofenac Sodium | Diclofenac Sodium | 234 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 208 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 73 |
| Fluoxetine Hcl | Fluoxetine Hcl | 198 | 59 |
| Ozempic | Semaglutide | 197 | 37 |
| Baclofen | Baclofen | 188 | 73 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 186 | 48 |
| Furosemide | Furosemide | 183 | 62 |
| Ibuprofen | Ibuprofen | 181 | 66 |
| Alprazolam | Alprazolam | 171 | 25 |
| Montelukast Sodium | Montelukast Sodium | 167 | 50 |
| Lorazepam | Lorazepam | 155 | 32 |
| Ketoconazole | Ketoconazole | 153 | 53 |
| Glimepiride | Glimepiride | 146 | 40 |
| Amoxicillin | Amoxicillin | 141 | 101 |
| Trazodone Hcl | Trazodone Hcl | 141 | 43 |
| Alendronate Sodium | Alendronate Sodium | 140 | 42 |
| Simvastatin | Simvastatin | 140 | 51 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 124 | 44 |
| Meloxicam | Meloxicam | 121 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 114 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 28 |
| Ezetimibe | Ezetimibe | 111 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 91 | 18 |
| Temazepam | Temazepam | 91 | 11 |
| Ciclopirox | Ciclopirox | 89 | 37 |
| Jardiance | Empagliflozin | 88 | 25 |
| Carvedilol | Carvedilol | 84 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 27 |
| Eliquis | Apixaban | 78 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 76 | 61 |
| Chlorthalidone | Chlorthalidone | 70 | 22 |
| Meclizine Hcl | Meclizine Hcl | 70 | 26 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 69 | 12 |
| Tramadol Hcl | Tramadol Hcl | 68 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 18 |
| Prednisone | Prednisone | 64 | 40 |
| Celecoxib | Celecoxib | 62 | 26 |
| Dexamethasone | Dexamethasone | 61 | 45 |
| Terbinafine Hcl | Terbinafine Hcl | 61 | 14 |
| Sertraline Hcl | Sertraline Hcl | 59 | 24 |
| Valsartan | Valsartan | 59 | 21 |
| Levofloxacin | Levofloxacin | 57 | 40 |
| Clonazepam | Clonazepam | 55 | 12 |
| Farxiga | Dapagliflozin Propanediol | 55 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 17 |
| Potassium Chloride | Potassium Chloride | 54 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 42 |
| Allopurinol | Allopurinol | 49 | 15 |
| Glipizide | Glipizide | 49 | 19 |
| Linzess | Linaclotide | 49 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 13 |
| Atenolol | Atenolol | 45 | 14 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 45 | 36 |
| Hydrocortisone | Hydrocortisone | 44 | 19 |
| Januvia | Sitagliptin Phosphate | 44 | 12 |
| Irbesartan | Irbesartan | 43 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 12 |
| Sucralfate | Sucralfate | 41 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | 13 |
| Benzonatate | Benzonatate | 37 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Nabumetone | Nabumetone | 36 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 16 |
| Mupirocin | Mupirocin | 35 | 17 |
| Trulicity | Dulaglutide | 35 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | 11 |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Azithromycin | Azithromycin | 32 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 31 | suppressed |
| Clotrimazole | Clotrimazole | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 12 |
| Fluconazole | Fluconazole | 28 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 11 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | 15 |
| Naproxen | Naproxen | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Tobramycin | Tobramycin | 22 | 20 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Finasteride | Finasteride | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $427.86 · 13 records | Bayer Healthcare Pharmaceuticals Inc. | ACCRUFER, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, REPATHA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error